Description
Ivodazumab Injection Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Ivodazumab Injection (lvonescimab) |
| Volume | 10ml per vial |
| Formulation | Injectable solution |
| Approval No. | China NMPA S20240020 |
| Drug Code | 86985204000011 |
| Manufacturer | Kangfang Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research only—Not for human or veterinary use |
Ivodazumab Injection Overview & Mechanism
Ivodazumab is a monoclonal antibody targeting a specific antigen involved in immune responses. It is utilized in research to study immune modulation and related pathways.
Ivodazumab Injection Research & Clinical Context
China NMPA Approval (Feb 2025): Approved for research purposes in immune-related studies.
Research Applications: Investigated in preclinical models for understanding immune mechanisms and potential therapeutic interventions.
Research Applications
Ideal for:
Immune modulation studies
Preclinical immune response models
Therapeutic target identification and validation
Pharmacokinetic and pharmacodynamic profiling
Handling & Storage
Storage: Store at 2–8°C, protected from light.
Handling: Use appropriate laboratory personal protective equipment (PPE); avoid ingestion or inhalation.
References
NMPA marketing approval for EGFR-mutant NSCLC pubmed.ncbi.nlm.nih.gov+3biopharmaapac.com+3prnewswire.com+3researchgate.net+9subsites.chinadaily.com.cn+9akesobio.com+9
Pivotal Phase III HARMONi data vs pembrolizumab
Mechanism of PD1/VEGF dual blockade
Phase I PK/PD assessment in solid tumors


bend –
I was recommended by a friend, it’s pretty good, thank you
abirahsa –
? ?????? ??? ???????. ??????????, ???? ??? ??? ?????? ???????, ??????? ???????? ????? PayPal. ????????. ???????, ?? ????? ??????? ???????!